The latest price target for MDxHealth (NASDAQ:MDXH) was reported by Piper Sandler on March 7, 2024. The analyst firm set a price target for $7.00 expecting MDXH to rise to within 12 months (a possible 163.16% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for MDxHealth (NASDAQ:MDXH) was provided by Piper Sandler, and MDxHealth maintained their overweight rating.

There is no last upgrade for MDxHealth

There is no last downgrade for MDxHealth.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MDxHealth, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MDxHealth was filed on March 7, 2024 so you should expect the next rating to be made available sometime around March 7, 2025.

While ratings are subjective and will change, the latest MDxHealth (MDXH) rating was a maintained with a price target of $6.00 to $7.00. The current price MDxHealth (MDXH) is trading at is $2.66, which is out of the analyst’s predicted range.